Drug safety evaluation of zonisamide for the treatment of epilepsy

Expert Opinion on Drug Safety

Volumn 10, Issue 4, 2011, Pages 623-631

  Zaccara, Gaetano ^a   Tramacere, Luciana ^a   Cincotta, Massimo ^a  

^a Hospital S Giovanni di Dio   (Italy)

Author keywords

adverse effects; antiepileptic drugs; epilepsy; long term studies; randomized clinical trial; review; safety; zonisamide

Indexed keywords

ACETAZOLAMIDE; ETIRACETAM; GABAPENTIN; OXCARBAZEPINE; PREGABALIN; SULTIAME; TIAGABINE; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

AGITATION; AMNESIA; ANOREXIA; ARTICLE; ASTHENIA; ATAXIA; BALANCE DISORDER; BEHAVIOR CHANGE; CONFUSION; CONTROLLED CLINICAL TRIAL; CRYSTALLURIA; DECREASED APPETITE; DEPRESSION; DIARRHEA; DIPLOPIA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRESS SYNDROME; DROWSINESS; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EOSINOPHILIA; EPILEPSY; FATIGUE; FLUID INTAKE; HEADACHE; HEAT; HUMAN; HYDRATION; HYPERAMMONEMIA; IRRITABILITY; LANGUAGE DISABILITY; LONG TERM CARE; MACULOPAPULAR RASH; MENTAL INSTABILITY; NAUSEA; NEPHROLITHIASIS; NERVOUSNESS; PATIENT SELECTION; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; STEVENS JOHNSON SYNDROME; SUICIDAL BEHAVIOR; SWEATING; THOUGHT DISORDER; TOXIC EPIDERMAL NECROLYSIS; TREATMENT DURATION; URTICARIA; WEAKNESS; WEIGHT REDUCTION;

ANIMALS; DRUG TOXICITY; EPILEPSY; HUMANS; ISOXAZOLES; KIDNEY CALCULI; MENTAL DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 79958853369     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2011.571201     Document Type: Article

References (88)

1. Leppik IE. Zonisamide. Epilepsia 1999;40 (Suppl 5):S23-9
2. Brodie MJ. Zonisamide as adjunctive therapy for refractory partial seizures. Epilepsy Res 2006;68 (Suppl 2):S11-16 (Pubitemid 43247592)
3. Kothare SC, Kaleyias J. Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin. Drug Metab Toxicol 2008;4:493-506 (Pubitemid 351728521)
4. Baulac M. Introduction to zonisamide. Epilepsy Res 2006;68 (Suppl 2):S3-9 (Pubitemid 43247591)
5. MacDonald RL. Zonisamide: mechanism of action. In: Levy R, Mattson R, Meldrum B, Perucca E. Antiepileptic drugs. 5th edition. Philadelpia, PA: Lippincott, Williams & Witkins Healthcare; 2002. p. 867-72
6. Suzuki S, Kawakami K, Nishimura S, et al. Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex. Epilepsy Res 1992;12:21-7
7. Rock DM, MacDonald RL, Taylor CP. Blockade of sustsained repetitive action potentials in cultured spinal cord neurons by zonisamide (AD 810, CI 912), a novel anticonvulsant. Epilepsy Res 1989;3:138-43 (Pubitemid 19071182)
8. Biton V. Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol 2007;30:230-40 (Pubitemid 47356720)
9. Kaneko S, Okada M, Hirano T, et al. Carbamazepine and zonisamide increase extracellular dopamine and serotonin levels in vivo, and carbamazepine does not antagonize adenosine effect in vitro: mechanisms of blockade of seizure spread. Jpn J Psychiatry Neurol 1993;47:371-3 (Pubitemid 23287449)
10. Ueda Y, Doi T, Tokumaru J, Wwillmore LJ. Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures. Brain Res Mol Brain Res 2003;116:1-6 (Pubitemid 36993691)
11. Okada M, Kawata Y, Mizuno K, et al. Interaction between Ca2+, K+, carbamazepine and zonisamide on hippocampal extracellular glutamate monitored with a microdialysis electrode. Br J Pharmacol 1998;124:1277-85 (Pubitemid 28333953)
12. Masuda Y, Karasawa T. Inhibitory effect of zonisamide on human carbonic anhydrase in vitro. Arzneimittelforschung 1993;43:416-18
13. Mori A, Noda Y, Packer L. The anticonvulsant zonisamide scavenges free radicals. Epilepsy Res 1998;30:153-8 (Pubitemid 28198243)
14. Mimaki T. Clinical pharmacology and therapeutic drug monitoring of zonisamide. Ther Drug Monit 1998;20:593-7 (Pubitemid 28544284)
15. Shah J, Shellenberger K, Canafax DM. Zonisamide: chemistry, biotranformation, and pharmacokinetics. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, editors, Antiepileptic drugs. 5th edition. Philadelphia, PA:Lippincott, Williams & Wilkins; 2002. p. 873-9
16. Sills GJ, Brodie MJ. Pharmacokinetics and drug interactions with zonisamide. Epilepsia 2007;48:435-41 (Pubitemid 46365198)
17. Biton V. Zonisamide: newer antiepileptic agent with multiple mechanisms of action. Expert Rev Neurother 2004;4:935-43 (Pubitemid 39482266)
18. Walker MC, Patsalos PN. Clinical pharmacokinetics of new antiepileptic drugs. Pharmacol Ther 1995;67:351-84
19. Oles KS, Bell WL. Zonisamide concentrations during pregnancy. Ann Pharmacother 2008;42(7):1139-41
20. Kawada K, Itoh S, Kusaka T, et al. Pharmacokinetics of zonisamide in perinatal period. Brain Dev 2002;24(2):95-7 (Pubitemid 34224911)
21. Schmidt D, Jacob R, Loiseau P, et al. Zonisamide for an add-on treatment of refractory epilepsy: a European double blind trial. Epilepsy Res 1993;15:67-73 (Pubitemid 23152402)
22. Faught E, Ayala R, Montouris GG, et al. Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology 2001;57:1774-9 (Pubitemid 33096682)
23. Sackellares JC, Ramsay RE, Wilder BJ, et al. Randomized, controlled, clinical trial of zonisamide as adjunctive treatment for refractory partial seizures. Epilepsia 2004;45:610-7 (Pubitemid 38802207)
24. Brodie MJ, Duncan R, Vespignani H, et al. Dose-dependent safety and efficacy of zonisamide: a randomized, double blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia 2005;46:31-41 (Pubitemid 40179930)
25. Otoul C, Arrigo C, van Rijckevorsel K, French JA. Meta-analysis and indirect comparisons of levetiracetam with other second-generation antiepileptic drugs in partial epilepsy. Clin Neuropharmacol 2005;28:72-8 (Pubitemid 40471880)
26. Chadwick DW, Marson AG. Zonisamide add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 2005;19;(4):CD001416
27. Zaccara G, Specchio LM. Long-term safety and effectiveness of zonisamide in the treatment of epilepsy: a review of the literature. Neuropsychiatr Dis Treat 2009;5:249-59
28. Marinas A, Villanueva V, Giraldez BG, et al. Efficacy and tolerability of zonisamide in idiopathic generalized epilepsy. Epileptic Disord 2009;11(1):61-6
29. Vossler DG, Conry JA, Murphy JV. Zonisamide for the treatment of myoclonic seizures in progressive myoclonic epilepsy: an open-label study. Epileptic Disord 2008;10(1):31-4 (Pubitemid 351507324)
30. You SJ, Kang HC, Kim HD, et al. Clinical efficacy of zonisamide in Lennox-Gastaut syndrome: Korean multicentric experience. Brain Dev 2008;30(4):287-90 (Pubitemid 351343864)
31. Lagae L. The need for broad spectrum and safe anti-epileptic drugs in childhood epilepsy. Acta Neurol Belg 2009;109(3):167-70
32. Zaccara G, Gangemi PF, Cincotta M. Central nervous system adverse effects of new antiepileptic drugs. A meta-analysis of placebo-controlled studies. Seizure 2008;17:405-21
33. Sirven JI, Fife TD, Wingerchuk DM, Drazkowski JF. Second-generation antiepileptic drugs impact on balance: a meta-analysis. Mayo Clin Proc 2007;82:40-7 (Pubitemid 46036320)
34. Berent S, Sackellares JC, Giordani B, et al. Zonisamide (CI-912) and cognition: results from preliminary study. Epilepsia 1987;28:61-7 (Pubitemid 17231448)
35. Park SP, Hwang YH, Lee HW, et al. Long-term cognitive and mood effects of zonisamide monotherapy in epilepsy patients. Epilepsy Behav 2008;12:102-8
36. White JR, Walczak TS, Marino SE, et al. Zonisamide discontinuation due to psychiatric and cognitive adverse events: a case-control study. Neurology 2010;75:513-18
37. Ojemann LM, Ojemann GA, Dodrill CB, et al. Language disturbances as side effects of topiramate and zonisamide therapy. Epilepsy Behav 2001;2:579-84 (Pubitemid 33586217)
38. Dodrill CB. Effects of sulthiame upon intellectual, neuropsychological, and social functioning abilities among adult epileptics: comparison with diphenylhydantoin. Epilepsia 1975;16:617-25
39. Park SP, Kim SY, Hwang YH, et al. Long-term efficacy and safety of zonisamide monotherapy in epilepsy patients. J Clin Neurol 2007;3:175-80
40. Weintraub D, Buchsbaum R, Resor SR, Hirsch LJ. Psychiatric and behavioral side effects of the newer antiepileptic drugs in adults with epilepsy. Epilepsy Behav 2007;10:105-10 (Pubitemid 46132156)
41. Michael CT, Starr JL. Psychosis following initiation of zonisamide. Am J Psychiatry 2007;164:682
42. Sullivan KL, Ward CL, Zesiewicz TA. Zonisamide-induced mania in an essential tremor patient. J Clin Psychopharmacol 2006;26:439-40 (Pubitemid 44187656)
43. Velasco PEB, Goiburu JAZ, Pinel RS. Restless legs syndrome induced by zonisamide. Mov Disord 2007;22:1517-18 (Pubitemid 47280649)
44. Azuma H, Negi A, Hattori M, et al. Neuroleptic malignant syndrome-like state in an epileptic patient with organic brain comorbidity treated with zonisamide and carbamazepine. Epilepsia 2007;48:1999-2001 (Pubitemid 47537443)
45. Zaccara G, Franciotta D, Perucca E. Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia 2007;48:1223-44 (Pubitemid 47063067)
46. Glauser TA, Pellock JM. Zonisamide in pediatric epilepsy: review of the Japanese experience. J Child Neurol 2002;17:87-96 (Pubitemid 34498435)
47. Alvestad S, Lydersen S, Brodtkorb E. Rash from antiepileptic drugs: influence by gender, age, and learning disability. Epilepsia 2007;48:360-5
48. Leppik IE. Practical prescribing and long-term effi cacy and safety of zonisamide. Epilepsy Res 2006;68 (Suppl 2):S17-24 (Pubitemid 43247593)
49. Teraki Y, Murota H, Izaki S. Toxic epidermal necrolysis due to zonisamide associated with reactivation of human herpesvirus 6. Arch Dermatol 2008;144:232-5 (Pubitemid 351287007)
50. Fujita Y, Hasegawa M, Nabeshima K, et al. Acute kidney injury caused by zonisamide-induced hypersensitivity syndrome. Inter Med 2010;49:409-13
51. Alvestad S, Lydersen S, Brodtkorb E. Cross-reactivity pattern of rash from current aromatic antiepileptic drugs Epilepsy Res 2008;80:194-200
52. Neuman MG, Shear NH, Malkiewicz IM, et al. Predicting possible zonisamide hypersensitivity syndrome. Exp Dermatol 2008;17:1045-51
53. Reilly TP, Ju C. Mechanisms perspectives on sulphonamide-induced cutaneous drug reactions. Curr Opin Allergy Clin Immunol 2002;2:307-15 (Pubitemid 36869639)
54. Nikaido K, Kato T, Takayama R, Doi T. [Valproate sodium and zonisamide associated interstitial pneumonitis in an infant]. No To Hattatsu 2007;39:44-8 (Pubitemid 46154143)
55. Esbaugh AJ, Tufts BL. The structure and function of carbonic anhydrase isozymes in the respiratory system of vertebrates. Respir Physiol Neurobiol 2006;54:185-98 (Pubitemid 44666578)
56. Pastorekova S, Parkkila S, Pastorek J, Supuran CT. Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. Enzyme Inhib Med Chem 2004;19:199-229 (Pubitemid 39004275)
57. Wroe S. Zonisamide and renal calculi in patients with epilepsy: how big an issue? Curr Med Res Opin 2007;23:1765-73 (Pubitemid 47300374)
58. Singh V, Muzina DJ, Calabrese JR. Anticonvulsants in bipolar disorder. Psychiatr Clin N Am 2005;28:301-23
59. Kinjo M, Setoguchi S, Schneeweiss S, Solomon DH. Bone mineral density in subjects using central nervous system-active medications. Am J Med 2005;118:1414.e7-1414.e12
60. Faught E. Review of United States and European clinical trials of zonisamide in the treatment of refractory partial-onset seizures. Seizure 2004;13 (Suppl 1):S59-65 (Pubitemid 39420027)
61. Paula E, Conant KD, Dunne IE, et al. Urolithiasis on the ketogenic diet with concurrent topiramate or zonisamide therapy. Epilepsy Res 2010;90:151-6
62. Chadwick DW, Marson AG. Zonisamide add-on for drug-resistant partial epilepsy. Cohrane Database Syst Rev 2002:CD001416
63. De Simone G, Supuran CT. Antiobesity carbonic anhydrase inhibitors. Curr Top Med Chem 2007;7:879-84 (Pubitemid 46830332)
64. Terry P, Gilbert DB, Cooper SJ. Dopamine receptor subtype agonists and feeding behavior. Obes Res 1995;3(Suppl 4):515S-523S
65. Wallingford NM, Sinnayah P, Bymaster FP, et al. Zonisamide prevents olanzapine-associated hyperphagia, weight gain, and elevated blood glucose in rats. Neuropsychopharmacology 2008;33:2922-33
66. Wang PW, Yang Y-S, Chandler RA, et al. Adjunctive zonisamide for weight loss in euthymic bipolar disorder patients: a pilot study. J Psychiatr Res 2008;42:451-7 (Pubitemid 351240917)
67. Leppik IE. Zonisamide: chemistry, mechanism of action, and pharmacokinetics. Seizure 2004;13(Suppl):S5-9 (Pubitemid 39420012)
68. Low PA, James S, Peschel T, et al. Zonisamide and associated oligohidrosis and hyperthermia. Epilepsy Res 2004;62:27-34 (Pubitemid 39424188)
69. Knudsen JF, Thambi LR, Kapcala LP, Racoosin JA. Oligohydrosis and fever in pediatric patients treated with zonisamide. Pediatr Neurol 2003;28:184-9 (Pubitemid 36593427)
70. Seki T, Kumagai N, Maezawa M. Effects of zonisamide monotherapy in children with epilepsy. Seizure 2004;13 (Suppl 1):S26-32 (Pubitemid 39420018)
71. Okumura A, Hayakawa F, Kuno K, Watanabe K. Oligohydrosis caused by zonisamide. No to Hattatsu 1996;28:44-7
72. Hosoda N, Niura H, Shirai H, et al. Clinical study on oligohydrosis in patients treated with zonisamide. Shonika Rinsyo 1996;49:2445-9
73. Kaliyadan F, Manoj J, Venkitakrishnan S. Xerosis and pityriasis alba-like changes associated with zonisamide. Indian J Dermatol Venereol Leprol 2008;74:165-6 (Pubitemid 351519601)
74. Shaikh AY, Muranjan MN, Gogtay NJ, Lahiri KR. Possible mechanism for zonisamide-induced hyperammonemia in a child with citrullinemia type 1. Indian J Med Sci 2009;63:203-6
75. Bookheimer S, Schrader LM, Rausch R, et al. Reduced anesthetization during the intracarotid amobarbital (Wada) testing patients taking carbonic anhydrase-inhibiting medications. Epilepsia 2005;46:236-43 (Pubitemid 40194667)
76. Kondo T, Kaneko S, Amano Y, Egawa I. Preliminary report on teratogenic effects of zonisamide in the offspring of treated women with epilepsy. Epilepsia 1996;37(12):1242-4 (Pubitemid 26415248)
77. Vajda FJ, Hitchcock AA, Graham J, et al. The teratogenic risk of antiepileptic drug polytherapy. Epilepsia 2010;51(5):805-10
78. Yamamura S, Hamaguchia T, Ohoyama K, et al. Topiramate and zonisamide prevent paradoxical intoxication induced by carbamazepine and phenytoin. Epilepsy Res 2009;84:172-86
79. Shinnar S, Pellock JM, Conry JA. Open-label, long-term safety study of zonisamide administered to children and adolescents with epilepsy. Eur J Paediatr Neurol 2009;13(1):3-9
80. Coppola G, Grosso S, Verrotti A, et al. Zonisamide in children and young adults with refractory epilepsy: An open label, multicenter Italian study. Epilepsy Research 2009;83:112-16
81. Murata M, Hasegawa K, Kanazawa I, The Japan Zonisamide on PD Study Group. Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study. Neurology 2007;68:45-50 (Pubitemid 46058551)
82. Zesiewicz TA, Ward CL, Hauser RA, et al. A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor. Mov Disord 2007;22:279-82 (Pubitemid 46374780)
83. Gadde KM, Franciscy DM, Wagner HR 2nd, Krishnan KR. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA 2003;289:1820-5 (Pubitemid 37430252)
84. McElroy SL, Kotwal R, Guerdjikova AI, et al. Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial. J Clin Psychiatry 2006;67:1897-906 (Pubitemid 46055195)
85. Gadde KM, Yonish GM, Foust MS, Wagner HR. Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study. J Clin Psychiatry 2007;68:1226-9 (Pubitemid 47395625)
86. Drake ME Jr, Greathouse NI, Renner JB, Armentbright AD. Open-label zonisamide for refractory migraine. Clin Neuropharmacol 2004;27:278-80 (Pubitemid 40066230)
87. Nuyen J, Schellevis FG, Satariano WA, et al. Comorbidity was associated with neurologic and psychiatric diseases: a general practice-based controlled study. J Clin Epidemiol 2006;59:1274-84 (Pubitemid 44708605)
88. Zaccara G. Neurological comorbidity and epilepsy: the implications for treatment. Acta Neurologica Scand 2009;120:1-15